THC

Tenet Healthcare Corp

Add to Watchlist

Advanced Chart

156.060

-0.46(-0.294%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

159.130

Open

156.850

VWAP

Vol

1.22M

Mkt Cap

14.50B

Low

155.580

Amount

EV/EBITDA(TTM)

6.95

Total Shares

97.68M

29.60B

EV/OCF(TTM)

12.01

P/S(TTM)

0.72

Tenet Healthcare Corporation is a diversified healthcare services company. The Company's segments include Hospital Operations and Services (Hospital Operations) and Ambulatory Care. The Hospital Operations segment is comprised of its acute care and specialty hospitals, a network of employed physicians and ancillary outpatient facilities. The Company's subsidiaries operate approximately 49 hospitals serving primarily urban and suburban communities in eight states. The Hospital Operations segment also includes around 135 outpatient facilities, including urgent care centers, imaging centers, off-campus hospital emergency departments and micro hospitals. It also provides revenue cycle management and value based care services. The Ambulatory Care segment, through its USPI Holding Company, Inc. subsidiary, holds ownership interests in approximately 518 ambulatory surgery centers, and 25 surgical hospitals in 37 states. The Company operates a Global Business Center in the Philippines.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

5.41B

+3.63%

4.307

-1.22%

5.37B

+5.8%

3.859

+12.17%

5.23B

+2.2%

3.172

+8.27%

Estimates Revision

The market is revising Upward the revenue expectations for Tenet Healthcare Corporation (THC) for FY2025, with the revenue forecasts being adjusted by 0.05% over the past three months. During the same period, the stock price has changed by 9.17%.

Revenue Estimates for FY2025

Revise Upward

+0.05%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.51%

In Past 3 Month

Stock Price

Go Up

+9.17%

In Past 3 Month

15 Analyst Rating

22.62% Upside

Wall Street analysts forecast THC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for THC is 191.36 USD with a low forecast of 154.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

1 Hold

0 Sell

Strong Buy

22.62% Upside

Current: 156.060

Low

154.00

Averages

191.36

High

230.00

22.62% Upside

Current: 156.060

Low

154.00

Averages

191.36

High

230.00

Wolfe Research

Outperform

Peer Perform

downgrade

2025-07-28

New

Reason

Wolfe Research

Price Target

2025-07-28

New

downgrade

Outperform

Peer Perform

Reason

Wolfe Research downgraded Tenet Healthcare to Peer Perform from Outperform without a price target. The firm cites the potential for healthcare exchange pressure in 2026 and provider tax pressure in 2028 and beyond for the downgrade. Wolfe now sees a less compelling risk/reward for the shares amid Tenet's legislative pressure.

Baird

Michael Ha

Neutral

downgrade

$195 -> $167

2025-07-25

New

Reason

Baird

Michael Ha

Price Target

$195 -> $167

2025-07-25

New

downgrade

Neutral

Reason

Baird analyst Michael Ha lowered the firm's price target on Tenet Healthcare to $167 from $195 and keeps a Neutral rating on the shares as part of an update on the managed care and healthcare facilities group. The firm is increasingly cautious on Medicaid and the healthcare exchange.

Barclays

Overweight

downgrade

$215 -> $208

2025-07-24

Reason

Barclays

Price Target

$215 -> $208

2025-07-24

downgrade

Overweight

Reason

Barclays lowered the firm's price target on Tenet Healthcare to $208 from $215 and keeps an Overweight rating on the shares post the Q2 report. The firm sees Affordable Care Act headwinds next year but says the concerns are overdone.

Morgan Stanley

NULL -> Overweight

maintain

$210 -> $225

2025-07-23

Reason

Morgan Stanley

Price Target

$210 -> $225

2025-07-23

maintain

NULL -> Overweight

Reason

Morgan Stanley raised the firm's price target on Tenet Healthcare to $225 from $210 and keeps an Overweight rating on the shares. The firm has increased estimates following "the strong beat," but did not flow all the Q2 upside through to 2026 given uncertainty around the path forward for exchanges, the analyst tells investors in a post-earnings note.

UBS

Buy

maintain

$230 -> $238

2025-07-23

Reason

UBS

Price Target

$230 -> $238

2025-07-23

maintain

Buy

Reason

UBS raised the firm's price target on Tenet Healthcare to $238 from $230 and keeps a Buy rating on the shares. Tenet's Q2 adjusted EBITDA was ahead of consensus by $125M, while the acute segment beat by $110M and the United Surgical Partners International segment was $15M ahead, the analyst tells investors in a research note. While uncertainty around the exchanges and Medicaid policy changes are a concern for hospitals, the firm expects USPI to continue delivering strong organic and inorganic growth.

Guggenheim

Jason Cassorla

Buy

maintain

$180 -> $188

2025-07-23

Reason

Guggenheim

Jason Cassorla

Price Target

$180 -> $188

2025-07-23

maintain

Buy

Reason

Guggenheim analyst Jason Cassorla raised the firm's price target on Tenet Healthcare to $188 from $180 and keeps a Buy rating on the shares after the company reported "hefty" Q2 EBITDA upside and raised 2025 guidance by over 10% at the midpoint. The firm believes a normalized multiple on its estimated 2026 sensitivity baseline "suggests continued solid upside" in shares following an earnings reaction that it calls "well overblown."

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tenet Healthcare Corp (THC.N) is 10.20, compared to its 5-year average forward P/E of 11.32. For a more detailed relative valuation and DCF analysis to assess Tenet Healthcare Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

11.32

Current PE

10.20

Overvalued PE

13.70

Undervalued PE

8.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

7.01

Current EV/EBITDA

6.69

Overvalued EV/EBITDA

7.53

Undervalued EV/EBITDA

6.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

0.41

Current PS

0.68

Overvalued PS

0.57

Undervalued PS

0.25

Financials

Annual

Quarterly

FY2025Q2

YoY :

+3.29%

5.27B

Total Revenue

FY2025Q2

YoY :

+8.67%

852.00M

Operating Profit

FY2025Q2

YoY :

+9.43%

522.00M

Net Income after Tax

FY2025Q2

YoY :

+18.94%

3.14

EPS - Diluted

FY2025Q2

YoY :

+23.42%

743.00M

Free Cash Flow

FY2025Q2

YoY :

+0.31%

78.37

Gross Profit Margin - %

FY2025Q2

YoY :

-16.92%

7.51

FCF Margin - %

FY2025Q2

YoY :

+5.88%

9.90

Net Margin - %

FY2025Q2

YoY :

-40.39%

10.11

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.8M

USD

3-6

Months

1.5M

USD

6-9

Months

0.0

USD

0-12

Months

19.6M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 337.36% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

460.1K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

788.6K

Volume

Months

6-9

180.3K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

8.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.8M

USD

3-6

Months

1.5M

USD

6-9

Months

0.0

USD

0-12

Months

19.6M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

THC News & Events

Events Timeline

2025-07-24 (ET)

2025-07-24

05:59:13

Bill would force hospitals to warn if not equipped to save preemies, WSJ says

2025-07-22 (ET)

2025-07-22

06:48:22

Tenet Healthcare sees 2025 EPS $15.55-$16.21, consensus $12.84

2025-07-22

06:46:48

Tenet Healthcare reports Q2 adjusted EPS $4.02 ,consensus $2.87

News

9.5

07-28NASDAQ.COM

ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%

4.0

07-28Benzinga

Wolfe Research Downgrades Tenet Healthcare to Peer Perform

2.0

07-27Benzinga

Chipotle Mexican Grill, Charter, And Fiserv Are Among Top 10 Large Cap Losers Last Week (July 21-July 25): Are The Others In Your Portfolio?

People Also Watch

Universal Health Services Inc

Jones Lang LaSalle Inc

CH Robinson Worldwide Inc

Dr Reddy's Laboratories Ltd

FAQ

What is Tenet Healthcare Corp (THC) stock price today?

The current price of THC is 156.06 USD — it has decreased -0.29 % in the last trading day.

THC

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

THC News & Events

Events Timeline

News

People Also Watch

FAQ

What is Tenet Healthcare Corp (THC) stock price today?

What is Tenet Healthcare Corp (THC)'s business?

What is the price predicton of THC Stock?

What is Tenet Healthcare Corp (THC)'s revenue for the last quarter?

What is Tenet Healthcare Corp (THC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Tenet Healthcare Corp (THC)'s fundamentals?

How many employees does Tenet Healthcare Corp (THC). have?

What is Tenet Healthcare Corp (THC) market cap?